Judy King, ASCO 2022: Highlights in breast cancer clinical trials – DESTINY-Breast04, DESTINY-Breast03, TROPiCS-02, CDK4/6 trial data, MAINTAIN study
DESTINY-Breast04 investigates the use of trastuzumab deruxtecan, in the first randomized clinical trial to show that targeting HER2 provides clinically meaningful benefits for patients with HER2-low metastatic breast cancer (0:10). Dr Judy King (Royal Free Hospital, London, UK) joined touchONCOLOGY to discuss the DESTINY-Breast04 trial results and major highlights in breast cancer presented ASCO 2022. In this interview, Dr King also discusses important data from longer term data presented from DESTINY-Breast03 (1:50), and also the phase 3 TROPiCS-02 trial (03:53), examining sacituzumab govitecan vs physicians’ choice chemotherapy for patients with hormone receptor–positive, HER2-negative advanced breast cancer. Dr King also discusses CDK4/6 trial data (cyclin-dependent kinases 4 and 6) (5:04) and overall survival results, and finally she looks at the phase 2 MAINTAIN study (5:36) which demonstrated the potential benefit of continued CDK 4/6 inhibition with hormone therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer who switched endocrine therapy and received the drug after progression on a CDK 4/6 inhibitor.
ASCO 2022 Abstracts discussed in this interview:
- Abstract #LBA3: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study
- A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
- Abstract #LBA1001: Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer
Disclosures: Judy King discloses advisory boards membership and speakers fee honoraria from Roche, BMS, Lilly, Novartis, Pfizer, ExactSciences, Prosigna/Veracyte, Eisai and Astra Zeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2022 American Society of Clinical Oncology (ASCO) annual meeting.
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!